Lonza's Niamax is a wax-matrix, extended-release niacin.
Researchers from the University of Minnesota have found Niamax, a slow-release niacin from Lonza (Basel, Switzerland), to be bioavailable and effective in improving fat profiles in people with high cholesterol. Niacin (vitamin B3) is frequently prescribed for cholesterol management.
After leading in with four weeks of a heart-healthy diet, 120 subjects were instructed to consume Niamax, inositol hexanicotinate (IHN), or placebo for six weeks. IHN is a popular “no-flush” form of niacin that doesn’t induce skin irritation (flushing), which some users experience from traditional niacin supplements.
By six weeks, the slow-release niacin was associated with lower total cholesterol (11%) and LDL cholesterol (18%), and higher HDL cholesterol (12%) compared to zero significant changes noted for IHN and placebo. As some subjects are sensitive to niacin, those who switched to a lower dose of Niamax still saw lipid improvements on par with the high dose.
A substudy on five subjects from each intervention group found that biomarkers of niacin absorption (nicotinuric acid, nicotinic acid, and nicotinamide) only rose with Niamax. This data influenced lead researcher Joseph Keenan, MD, to question the use of IHN supplements altogether.
“This study concluded that the nicotinic acid in IHN is not bio-available, and there’s no evidence that it reaches the therapeutic levels needed to alter lipids; therefore, it has no place in the management of high cholesterol,” said Keenan. “In fact, this study raises the ethical issue of whether IHN has any benefit at all even as a vitamin supplement.”
Illustrations of the effect of Niamax and IHN on niacin biomarkers are provided at the link above. The study is published in the Journal of Clinical Lipidology.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
Published: May 14th 2024 | Updated: May 15th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.